Cancer-Fighting Biotechs Jump 1,000% in Shadow of Covid Stocks
- Pair of biotech stocks have surged more than tenfold in 2020
- Stocks have rallied by focusing on drugs, not chasing Covid-19
This article is for subscribers only.
A pair of biotech companies fighting yet another modern disease - cancer - have seen their shares soar over 1,000% this year.
Investors’ optimism on promising results on cancer-fighting platforms by Cardiff Oncology Inc. and Trillium Therapeutics Inc. has propelled the duo to the group of five best performers in the Nasdaq Composite Index of nearly 3,000 stocks. While Covid-19 has dominated headlines, boosting shares of companies involved in vaccines, cancer therapies and even treatments for easily-spread bacterial infections remain an area for investors to make millions.